BiotechTube

Povorcitinib + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Oct 10, 2024 → May 3, 2027

NCT ID
NCT06516965

About Povorcitinib + Placebo

Povorcitinib + Placebo is a phase 3 stage product being developed by Incyte for Prurigo Nodularis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06516965. Target conditions include Prurigo Nodularis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (7)

NCT IDPhaseStatus
NCT06516952Phase 3Recruiting
NCT06516965Phase 3Recruiting
NCT06113445Phase 3Active
NCT06113471Phase 3Active
NCT05936567Phase 2Completed
NCT05620836Phase 3Completed
NCT05620823Phase 3Completed

Competing Products

20 competing products in Prurigo Nodularis

See all competitors
ProductCompanyStageHype Score
Vixarelimab + PlaceboKiniksa PharmaceuticalsPhase 2
47
UpadacitinibAbbVieApproved
85
Pimecrolimus + Hydrocortisone + PimecrolimusNovartisPhase 2
52
Rocatinlimab + PlaceboAmgenPhase 3
76
AbrocitinibPfizerPhase 2
51
Dupilumab SAR231893 (REGN668)SanofiPre-clinical
22
DupilumabSanofiPhase 3
76
DupilumabSanofiPre-clinical
22
DupilumabSanofiPre-clinical
22
Ruxolitinib Cream 1.5%IncytePhase 1
30
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
CDX-0159 + Normal salineCelldex TherapeuticsPhase 1
28
barzolvolimabCelldex TherapeuticsPhase 2
47
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsTrevi TherapeuticsPhase 2/3
60
serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74